Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial

INTRODUCTION: Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma. Results from the BOLT study demonstrated robust efficacy and continued tolerability through 42 months. This analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Karl, Dummer, Reinhard, Farberg, Aaron S., Guminski, Alexander, Squittieri, Nicholas, Migden, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611137/
https://www.ncbi.nlm.nih.gov/pubmed/34669179
http://dx.doi.org/10.1007/s13555-021-00619-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611137/
https://www.ncbi.nlm.nih.gov/pubmed/34669179
http://dx.doi.org/10.1007/s13555-021-00619-4

Ejemplares similares